| Kathleen Anne Goyne, MD | |
|
1109 Burleyson Rd Ste 104, Dalton, GA 30720-3094 | |
| (706) 281-8490 | |
| (706) 529-8487 |
| Full Name | Kathleen Anne Goyne |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 36 Years |
| Location | 1109 Burleyson Rd Ste 104, Dalton, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427240175 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD024935 (Tennessee) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 91524 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hamilton Physician Group, Inc | 4789708553 | 100 |
News Archive
Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
Data from a new Mayo Clinic study suggest that dietary therapy using flaxseed can decrease hot flashes in postmenopausal women who do not take estrogen.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.
HHS and private insurance companies will share raw data and investigations to try to stop billions of dollars in fraud.
› Verified 4 days ago
| Entity Name | Hamilton Physician Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235455569 PECOS PAC ID: 4789708553 Enrollment ID: O20100831000467 |
News Archive
Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
Data from a new Mayo Clinic study suggest that dietary therapy using flaxseed can decrease hot flashes in postmenopausal women who do not take estrogen.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.
HHS and private insurance companies will share raw data and investigations to try to stop billions of dollars in fraud.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathleen Anne Goyne, MD Po Box 1587, Dalton, GA 30722-1587 Ph: (706) 281-8490 | Kathleen Anne Goyne, MD 1109 Burleyson Rd Ste 104, Dalton, GA 30720-3094 Ph: (706) 281-8490 |
News Archive
Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
Data from a new Mayo Clinic study suggest that dietary therapy using flaxseed can decrease hot flashes in postmenopausal women who do not take estrogen.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.
HHS and private insurance companies will share raw data and investigations to try to stop billions of dollars in fraud.
› Verified 4 days ago
Dr. Linda Kay Norman, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 203 N Thornton Ave, Dalton, GA 30720 Phone: 706-275-8104 Fax: 706-275-8134 | |
Carlos H Perez, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1102 W Waugh St, Dalton, GA 30720 Phone: 706-277-2321 Fax: 706-428-2812 | |
Ashish Mohammad Kabir, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1107 Memorial Dr Ste 102, Dalton, GA 30720 Phone: 706-275-6121 Fax: 706-275-0521 | |
Dr. Rhonda Vought, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1414 Dug Gap Rd, Dalton, GA 30720 Phone: 706-279-0405 Fax: 706-279-4190 | |
Dr. Muhammad Aslam Sandvi, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1421 Ross Dr, Suite1, Dalton, GA 30720 Phone: 706-278-2962 Fax: 706-226-0746 | |
Dr. Harleen Singh, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 475 Reed Rd Ste 104, Dalton, GA 30720 Phone: 706-529-8710 Fax: 706-529-8715 |